Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders on March 3, 2026, but it was adjourned for one week because there were not enough shareholders present to form a quorum. The Meeting is now scheduled to reconvene on March 10, 2026 at 3:00 p.m., Israel time.
The reconvened Meeting will take place at the Company’s offices at 26 Ben Gurion Street, Ramat Gan, Israel. This update simply informs shareholders of the new date, time and place so they can attend and participate in the Meeting.
Can-Fite BioPharma filed a 6-K describing a new peer-reviewed publication showing an anti-obesity effect of its lead drug candidate, namodenoson. In cell and high-fat diet mouse models, namodenoson reduced adipocyte proliferation, lipid accumulation, and weight gain, while modulating metabolic and inflammatory pathways such as adiponectin, PI3K, NF-κB, Akt, and Wnt/β-catenin.
The findings align with earlier Phase IIa data in MASH patients, where three months of treatment was associated with reduced liver fat and body weight, and support further evaluation of namodenoson as a potential oral obesity treatment. Namodenoson is already in Phase III for advanced liver cancer and Phase IIb for MASH, and the company notes obesity as a rapidly growing market projected to reach $60.5 billion by 2030.
Can-Fite BioPharma Ltd. reports that the Canadian Patent Office has issued a notice of allowance for a patent covering its oral drug Namodenoson as an anti-obesity therapy. The patent protects the use of this A3 adenosine receptor agonist to reduce fat mass and body weight in Canada.
The patent stems from data showing Namodenoson increased adiponectin, a hormone that regulates fat production, reduced body weight in an obesity animal model, and produced a 2.3% weight loss over three months in a MASH Phase IIa study. Can-Fite already holds similar Namodenoson obesity patents in the United States and Australia.
Namodenoson is also in Phase III for advanced liver cancer, Phase IIb for MASH, and Phase IIa for pancreatic cancer, and has shown an excellent oral safety profile across multiple clinical studies. Can-Fite highlights that expanding intellectual property into metabolic indications like fat loss may support future development and partnering, within a global obesity treatment market projected to reach $60.5 billion by 2030 with a ~22% CAGR.
Can-Fite BioPharma reports a single compassionate-use case in which its liver drug candidate Namodenoson helped clinically stabilize a patient with advanced decompensated cirrhosis until a compatible donor became available, enabling a successful liver transplantation. Physicians describe this as an encouraging observation but stress that individual cases must be interpreted with caution.
Namodenoson is an orally bioavailable A3 adenosine receptor agonist with anti-inflammatory and anti-fibrotic properties and a favourable safety profile in prior studies. It is being tested in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for MASH, and a Phase IIa study in pancreatic cancer. Can-Fite also highlights its broader pipeline, including Piclidenoson for psoriasis and CF602 for erectile dysfunction.
Can-Fite BioPharma Ltd. reports that it received a notice of non-compliance from NYSE American because its audit committee currently has fewer than three independent members following an independent director’s resignation. The company has until the earlier of its next annual shareholder meeting or January 14, 2027 (or, if that meeting is held before July 13, 2026, until July 13, 2026) to regain compliance, and its ADSs continue to trade on NYSE American under the symbol CANF.
To address this, Can-Fite has called a Special General Meeting for March 3, 2026 in Ramat Gan, Israel. Shareholders and ADS holders of record as of February 5, 2026 will vote on electing Ilan Tamir as an external director, with the expectation that he will join the audit committee, helping restore compliance. They will also vote on granting each non-executive director (excluding the executive chair) 16,000 options at an exercise price of NIS 6.767 per ordinary share under the 2023 Share Option Plan and on adopting a renewed compensation policy that updates salary ranges, benefits, equity incentives and a detailed clawback framework for incentive-based pay.
Can-Fite reports 2,618,424 ordinary shares outstanding as of January 26, 2026, each carrying one vote at the meeting, with specific quorum and majority rules, including special approval thresholds for certain pay-related items involving controlling or interested shareholders.
Can-Fite BioPharma Ltd. reports a clinical milestone, completing patient enrollment in its Phase 2a pancreatic cancer study of its liver drug Namodenoson. The multicenter, open-label trial includes patients with advanced pancreatic adenocarcinoma whose disease has progressed after at least one prior therapy and is focused primarily on safety, with additional evaluation of clinical activity and pharmacokinetics.
Patients receive 25 mg oral Namodenoson twice daily in continuous 28‑day cycles, and the company states that Namodenoson has shown a favorable safety profile to date, indicating the primary safety endpoint has been demonstrated so far. Can-Fite expects top-line efficacy data from this study in Q3 2026. Namodenoson, a selective A3 adenosine receptor agonist, holds FDA Orphan Drug Designation for pancreatic cancer and is also in Phase 3 and Phase 2 trials for other liver indications.
Can-Fite Biopharma Ltd. filed a Form 6-K reporting that board member Yaacov Goldman resigned from its Board of Directors and all board committees, effective immediately on January 14, 2026. The company states that Mr. Goldman resigned for personal reasons and that his departure was not due to any disagreement with the company regarding its operations, policies, or practices. The report is also incorporated by reference into Can-Fite’s existing registration statements on Form S-8 and Form F-3, meaning those registration statements now include this update.
Can-Fite BioPharma Ltd. filed a Form 6-K as a foreign private issuer describing a recent corporate update. The company reports that on December 26, 2025 it issued a press release titled “Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction,” highlighting patent protection in Brazil for a sexual dysfunction treatment.
The press release is furnished as Exhibit 99.1 and is incorporated by reference into Can-Fite’s existing shelf and employee benefit plan registration statements on Forms S-8 and F-3, making the patent-related disclosure part of those securities offering documents.
Can-Fite BioPharma Ltd. furnished a report noting that it issued a press release titled “Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change.” The company states that this press release, dated December 23, 2025, is incorporated by reference into its existing Form S-8 and Form F-3 registration statements. The report is signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer.